Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 178 pages

Showing 101 - 150


solid tumors

Lawrence H. Einhorn, MD, on Testicular Cancer: The Keynote Lecture

Lawrence H. Einhorn, MD, of the Indiana University Simon Cancer Center, summarizes his keynote lecture on the controversies in management of clinical stage I testicular cancer and the long-term consequences of platinum combination chemotherapy.

solid tumors
survivorship

Mohammad Abu Zaid, MD, on Testicular Cancer: Study Results on Metabolic Syndrome

Mohammad Abu Zaid, MD, of Indiana University Simon Cancer Center, discusses findings from a multicenter study of North American testicular cancer survivors, their prevalence of hypertension, risk factors for metabolic syndrome, and the need for screening and treatment (Abstract 102).

solid tumors

‘Collateral Lethality’ May Offer New Therapeutic Approach for Cancers of the Pancreas, Stomach, and Colon

Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for development of therapies for several cancers. Scientists at The University of Texas MD ...

solid tumors

FDA Grants Priority Review to Pembrolizumab for New Indication in Microsatellite Instability–High Cancer

On November 28, the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda) for the treatment of previously treated patients with advanced microsatellite instability–high (MSI-H) cancer. The FDA granted...

solid tumors
hematologic malignancies
skin cancer

SITC 2016: Phase I/II Data Combining Urelumab With Nivolumab Suggest Increased Antitumor Effect in Patients With Melanoma

Safety and efficacy data from a phase I/II study of urelumab in combination with nivolumab (Opdivo) in patients with hematologic and solid tumors, including biomarker analyses by level of programmed death ligand 1 (PD-L1) expression, was recently presented at the Society for Immunotherapy of Cancer ...

solid tumors
hematologic malignancies

ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600–Mutated Tumors

Findings from a phase II trial of vemurafenib in previously treated patients with advanced disease and BRAF-mutated tumors indicate that the drug is effective in patients with diverse BRAF V600­–mutated tumors but not in patients with BRAF non-V600 mutations. After a mean treatment...

solid tumors
palliative care

Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near End of Life (French Language Version)

Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses in French his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especially in young patients treated in high-volume centers without a palliative care unit....

solid tumors
palliative care

Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near the End of Life

Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especially in young patients treated in high-volume centers without a palliative care unit. (Abstract...

genomics/genetics
solid tumors

Janessa J. Laskin, MD, on Tumor Gene Expression and Advanced Cancers

Janessa J. Laskin, MD, of the British Columbia Cancer Agency, discusses the ways in which availability of tumor gene expression data facilitates clinical decision-making for patients with advanced cancers. (Abstract 1519O)

solid tumors
gynecologic cancers

CA-125 Tests and CT Scans Still Routinely Used for Surveillance in Ovarian Cancer, Yet Benefit Remains Unproved

As reported by Esselen et al in JAMA Oncology, cancer antigen 125 (CA-125) tests and computed tomography (CT) scans for surveillance in women with ovarian cancer continue to be used routinely, although their benefit has not been proven and the practices have significant quality-of-life and economic ...

solid tumors
issues in oncology

Insurance Status Impacts Survival, According to Two New Studies

Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study found. The findings, published by Markt et al in Cancer, add to growing evidence that differences in health insurance status can affect...

solid tumors

CAR T-Cell Therapy Using Double Target Aimed at Solid Tumors in Preclinical Models

Chimeric antigen receptors (CARs), engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues containing the protein targeted by the engineered cells. Now, in a report published...

solid tumors

SNMMI 2016: Personalized Kidney Dosimetry Optimizes Radiotherapy Dose in Patients With Neuroendocrine Tumors

Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a molecular imaging technique that allows oncologists to set patients’ radiotherapy doses right at that critical limit of delivering the most powerful dosage to neuroendocrine...

solid tumors

SNMMI 2016: A Blood-Based Multi-Transcript Test May Predict Success of Neuroendocrine Cancer Therapy

Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an investigative blood test could...

solid tumors

Investigational Drug Abemaciclib Shows Promising Activity Against Several Cancer Types in Early Study

An experimental CDK inhibitor, abemaciclib, yielded encouraging and durable results against several different types of cancers, including breast cancer, lung cancer, glioblastoma, and melanoma, according to a report published by Patnaik et al in Cancer Discovery. The results of the trial supported ...

solid tumors

John D. Hainsworth, MD, on Advanced Solid Tumors: Results From the MyPathway Trial

John D. Hainsworth, MD, of the Sarah Cannon Research Institute, discusses early findings from this umbrella basket study on targeted treatment, outside of current drug indications, for different types of advanced solid tumors (Abstract LBA11511).

solid tumors

ASCO 2016: Liquid Biopsy May Help Guide Treatment Decisions for Patients With Advanced Solid Tumors

A large-scale genomic analysis found that patterns of genetic changes detected in blood samples (liquid biopsy) closely mirror those identified in traditional tumor biopsy. With blood samples from more than 15,000 patients and 50 different tumor types, this is one of the largest cancer genomics...

solid tumors

ASCO 2016: Precision Medicine Approach May Expand Therapeutic Options for Patients

Researchers reported encouraging early results from a phase II trial that matches patients with molecular abnormalities in the tumor to corresponding targeted treatments. Twenty-nine of 129 patients with 12 different types of advanced cancers responded to drugs outside of U.S. Food and Drug...

solid tumors

FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) today approved Netspot, the first kit for the preparation of Ga-68 dotatate injection, a radioactive diagnostic agent for positron-emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with...

solid tumors

ESTRO 2016: Radiotherapy vs Chemotherapy in a Study of Patients With Early Stage II Testicular Cancer

A large study of testicular cancer patients showed that radiation therapy was more effective than chemotherapy for patients with stage IIa disease (where one or more regional lymph nodes contain cancer cells, but they are less than 2 cm in diameter). These findings, presented at the ESTRO 35...

solid tumors

Study Finds Cancer Mortality Risks From Long-Term Exposure to Ambient Fine Particulate Matter

Long-term exposure to ambient fine particulate matter, a mixture of environmental pollutants, was associated with increased risk of mortality for many types of cancer in an elderly Hong Kong population, according to a study published by Wong et al in Cancer Epidemiology, Biomarkers &...

solid tumors

ESTRO 2016: Radiation and L19-IL2 Immunotherapy Combination Shows Activity in Preclinical Models

Radiation therapy not only targets and destroys cancer cells, but also helps to activate the immune system against their future proliferation. However, this immune response is often not strong enough to be able to completely eradicate tumors, and even when it is, its effect is limited to the area...

solid tumors

Modified CAR T Cells Overcome Immune Suppression, Effective Against Solid Tumors in Preclinical Models

Adding a genetically engineered “switch receptor” to second-generation CAR T cells blocked PD-1–mediated immune suppression, and made the immunotherapy effective against solid tumors in preclinical models, according to a study published by Liu et al in Cancer Research....

solid tumors

Comprehensive Genomic Analysis Reveals New Genetic Insights Into Malignant Mesothelioma

Malignant mesothelioma is a rare but deadly form of cancer; the 5-year survival rate for patients diagnosed with the disease is between 5% and 10%. Although aggressive surgery can help some patients with early-stage mesothelioma, current treatments for patients with more advanced mesothelioma are...

solid tumors
issues in oncology

American College of Physicians Issues Advice, Raises Questions About Best Practices for Hematuria as a Sign of Cancer

In some patients, blood in the urine, or hematuria, may be the only warning sign of cancer in the urinary tract. A new report from the American College of Physicians’ (ACP) High Value Care Task Force published by Nielsen et al in Annals of Internal Medicine issues advice for physicians on how ...

palliative care
solid tumors

2016 GI Symposium: New Regimen for Locally Advanced Rectal Cancer as Effective as, but Less Toxic Than, Chemoradiation

Findings from a Polish phase III study point to an additional treatment option for patients with advanced rectal cancer. Patients who received short-course (5-day) radiation followed by consolidation chemotherapy before surgery achieved  outcomes similar to those of patients treated with...

solid tumors
prostate cancer

GU Symposium 2016: Regular Aspirin Use May Reduce Risk of Dying From Prostate Cancer

A large observational study has found that men who take aspirin regularly may have a lower risk of dying from prostate cancer. Men who took aspirin regularly after their prostate cancer diagnosis were less likely to die from the disease. However, aspirin did not affect the overall incidence of...

solid tumors

Felice Schnoll-Sussman, MD, Named Director of Jay Monahan Center for Gastrointestinal Health at NewYork-Presbyterian/Weill Cornell 

NewYork-Presbyterian/Weill Cornell Medical Center has appointed Felice Schnoll-Sussman, MD, Director of its Jay Monahan Center for Gastrointestinal Health. Dr. Schnoll-Sussman, has served as the Center’s Director of Research since 2007 and Acting Director since 2012. As Director, Dr....

solid tumors

Gastric Cancer Foundation Announces Research Partnership With AGA

The Gastric Cancer Foundation recently announced the formation of a research partnership with the American Gastroenterological Association (AGA) and a confirmed timeline for awarding newly funded research grants for upper gastrointestinal tract cancers. Wayne Feinstein, Chairman of the Board of...

solid tumors

Oncologists Tell Inspiring Stories of What It’s  Like to Treat Cancer in The Big Casino

Title: The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful StoriesEditors: Stan Winokur, MD, and Vincent CoppolaPublishing Platform: CreateSpacePublication date: May 2014Price: $9.99; Paperback, 160 pages   In May, Stan Winokur, MD, and co-editor Vincent Coppola, published The...

solid tumors

Extraordinary Medical Advances and the Conundrum They Pose

BOOKMARK Title: Ordinary Medicine: Extraordinary Treatments, Longer Lives, and Where to Draw the LineAuthor: Sharon R. KaufmanPublisher: Duke University PressPublication date: May 29, 2015Price: $26.95 paperback, 336 pages Medicine has changed radically over the past 15 years. Who doesn’t welcome...

solid tumors

Mental Health Status Prior to Radical Cystectomy Can Indicate Risk of Complications

A patient's mental health prior to surgery can influence postoperative outcomes. Removal of the bladder, or radical cystectomy, is an effective treatment for locally advanced bladder cancer, but complications occur in as many as 66% of patients. In a study published by Sharma et al in The Journal...

solid tumors

Fractionated Stereotactic Radiation More Effective Than Single-Dose Radiation in Pituitary Tumors

A recent study at Houston Methodist Hospital proved that multiple small doses of highly focused radiation therapy is safer and more effective than a single larger dose of radiation at destroying pituitary gland tumors. The findings on the use of fractionated stereotactic radiotherapy were published ...

issues in oncology
solid tumors

Biomarker miR-506 Helps Predict Survival Time in Gastric Cancer Patients

Gastric cancer is typically associated with late-stage diagnosis, as well as high mortality. A study by Li et al in The American Journal of Pathology points to a pivotal role played by the biomarker microRNA (miR)-506 in gastric cancer. Patients whose primary gastric cancer lesions express high...

solid tumors
lung cancer
cns cancers

ECC 2015: Lung and Gastrointestinal Neuroendocrine Tumors and Results From the RADIANT-4 Trial

An international team of researchers has shown that the use of the mTOR inhibitor everolimus can delay tumor growth among both gastrointestinal and lung neuroendocrine tumors. This is particularly important for patients with lung tumors, the researchers say, because there is currently no approved...

cns cancers
solid tumors

ECC 2015: Advanced Gastrointestinal Neuroendocrine Tumors and Results From the NETTER-1 Trial

Results from a multicenter randomized international trial of an innovative treatment show a marked improvement in the length of time patients with midgut neuroendocrine tumors experience progression-free survival, researchers reported at the 2015 European Cancer Congressin Vienna, Austria, on...

solid tumors

ECC 2015: Use of Aspirin Linked to Improved Survival in Gastrointestinal Cancers

Aspirin improved survival in patients with tumors situated throughout the gastrointestinal tract, results from a large study in the Netherlands showed. This is the first time that survival data from patients with tumors in different gastrointestinal locations have been analyzed at the same time;...

lung cancer
solid tumors

Statistical Model May Identify Patients Most Likely to Benefit From Mesothelioma Surgery

A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma, according to a report published by Leuzzi et al in The Annals of Thoracic Surgery. Malignant pleural mesothelioma is an aggressive...

colorectal cancer
solid tumors

Synchronous vs Sequential Tumor Resection in Patients With Advanced Colorectal Cancer

About 20% of patients with colorectal cancer have cancers that have metastasized beyond the colon at the time of their diagnosis, with the liver being the most common site for these metastases. The approach to treating primary tumors within the colon and metastatic tumors in the liver continues to...

colorectal cancer
solid tumors
pancreatic cancer
supportive care

ESMO World GI 2015: SENRI Trial Evaluates NK1 Antagonists for Emesis Prevention in Oxaliplatin-Based Chemotherapy

The SENRI trial has opened the window to evaluate neurokinin 1 (NK1) antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, said European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO) spokesperson and antiemetics expert Fausto Roila, MD....

solid tumors
issues in oncology

ASCO 2015: Biomarker Analysis Reveals Several Potential Treatment Targets in Subtype of Anal Cancer

Squamous cell anal carcinomas are rare, representing only about 2% of gastrointestinal cancer diagnoses. These cancers, which are associated with the human papillomavirus (HPV), sometimes prove very difficult to treat, recurring or developing metastases following standard treatment. Seeking to...

colorectal cancer
solid tumors
lung cancer

ASCO 2015: Entolimod May Be a Promising Treatment Option for Many Solid Tumors

A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute, shared results from the first clinical study of the anticancer effects of the novel agent entolimod on May 30 at the 2015 ASCO Annual Meeting in Chicago (Abstract 3063). Their findings confirm ...

solid tumors

ASCO 2015: Bevacizumab Combination Boosts Survival in Advanced Stomach and Esophageal Cancers

Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination. Scientists at Dana-Farber Cancer Institute, who led the research, will report these...

colorectal cancer
solid tumors
gynecologic cancers

ASCO 2015: Mismatch Repair Deficiency Predicts Response to Pembrolizumab Among Patients With Colorectal and Other Cancers

A phase II study identified the first genomic marker—mismatch repair deficiency—to predict clinical benefit of immune checkpoint blockade with the anti–PD-1 antibody pembrolizumab (Keytruda). Among 50 patients with colorectal cancer, 62% of the 25 patients with mismatch...

colorectal cancer
solid tumors
issues in oncology
issues in oncology
issues in oncology

Study Finds Noninvasive Colon Cancer Screening May Be Promising for African Americans

In a first-of-its-kind clinical trial, physician-scientists at University Hospitals (UH) Case Medical Center, Seidman Cancer Center, and Case Western Reserve University School of Medicine found that a new, noninvasive technology for colon cancer screening is a promising alternative to colonoscopy...

gynecologic cancers
solid tumors
gynecologic cancers
head and neck cancer
issues in oncology

Nine-Valent HPV Vaccine Protects Against 80% of Cervical Cancers

The new nine-valent human papillomavirus (HPV) vaccine (Gardasil 9) can potentially prevent 80% of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus. Additionally, the new vaccine, which includes seven cancer-causing...

solid tumors
issues in oncology
sarcoma
issues in oncology

Population-Based Study Finds Patients With Gastrointestinal Tumors at Higher Risk of Other Cancers

Researchers at the University of California (UC) San Diego School of Medicine conducted the first population-based study that characterizes the association and temporal relationship between gastrointestinal stromal tumors (GIST) and other cancers. The results, published by Murphy et al in Cancer,...

breast cancer
gynecologic cancers
prostate cancer
issues in oncology
solid tumors

AACR 2015: New PARP Inhibitor Combination Shows Early Promise for a Wide Range of Cancer Patients

A combination of two molecularly targeted drugs, olaparib (Lynparza) and the investigational agent AZD5363, was safe and yielded responses in patients with a variety of cancer types, including breast, ovarian, and prostate cancers, regardless of BRCA1/2-mutation status, according to data from the...

colorectal cancer
solid tumors
issues in oncology
gastroesophageal cancer

AACR 2015: Long-Term, Regular Aspirin Use Modestly Decreased Cancer Risk

Long-term, regular aspirin use was associated with a modestly reduced overall risk for cancer, driven primarily by a reduction in the risk for colorectal cancers, according to research presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract 876). “Previous...

solid tumors

AACR 2015: Pembrolizumab Safe, With Signs of Clinical Benefit, for Patients With Malignant Pleural Mesothelioma

Pembrolizumab (Keytruda) was safe, tolerable, and yielded robust antitumor responses in patients with malignant pleural mesothelioma, according to data from the phase Ib KEYNOTE-028 clinical trial presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract CT103)....

Advertisement

Advertisement



;
Advertisement